CA
NZ
UK
AU
IND
US
In January 2026 Nuvation Bio announced aPartnershipwith Eisai to commercialize taletrectinib, the active ingredient in IBTROZI, in Europe and other territories outside the United States, China and Japan. The upfront payment lifted nine-month license revenue by USD 58.7 million. The European Medicines Agency validated …
Key HighlightsEnvista Holdings (NYSE:NVST) reported third-quarterDiluted Earnings per Shareof USD 3.11, compared with a loss of USD 0.18 a year earlier, withNet Incomeof USD 508.3 million versus a loss of USD 30.3 million.A realized cumulative foreign currency translation gain of USD 428.1 million, recorded …
Dow Jones revenue rose 8% to USD 630 million, with segment EBITDA up 11% to USD 160 million. Average subscriptions to its news products topped 6.9 million, up 8%, andWall StreetJournalsubscriptions grew 9% to 5.0 million. Digital Real Estate Services revenue rose 10% to …
Expenses fell to USD 221.9 million from USD 259.9 million as average borrowings dropped from USD 9.6 billion to USD 8.3 billion and the average rate eased from 5.8% to 5.4%. The quarter itself showed a net gain, with unrealized gains of USD 12.8 …
Gross profit rose USD 5.2 million to USD 90.8 million. The company credited a USD 27.4 million combined benefit from European emission allowance timing and higher raw material pass-through, offset by lower Rubber Carbon Black contract pricing of USD 10.6 million and USD 10.5 …
On March 31, 2026, the company closed a private placement with gross proceeds of about USD 150.0 million before USD 9.6 million of fees and expenses. Investors bought 26.7 million shares at USD 4.15 each plus pre-funded warrants over 9.4 million shares, which were …
Gross margin improved 1.3 points in the quarter and 3.8 points over nine months, which the company tied to better service margins despite a lower mix of higher-margin consumables. Total operating expenses fell to USD 25.9 million from USD 27.4 million, as sales and …
GAAP net income was USD 9.0 million, or USD 0.24 per diluted share, versus USD 8.4 million, or USD 0.21. The company said the per-share gain also reflects a lower share count after it redeemed its Series A-2 Preferred Stock last year and repurchased …
Selling, general and administrative expenses rose 3.2% to USD 177.6 million, which the company attributed mainly to merger transaction costs. Net interest expense fell to USD 12.9 million from USD 14.1 million. The Other, net line swung to a USD 1.0 million gain from …
The loss from continuing operations was USD 35.6 million, or USD 0.05 per share, compared with USD 32.9 million, or USD 0.04. Operating loss narrowed to USD 31.4 million asResearch and Developmentrose to USD 32.2 million. Discontinued operations lost USD 18.0 million after earning …
Please wait processing your request...